Recent news on Fosamax Plus D

FDA Approves New Dosage Strength Of FOSAMAX PLUS D  -  May 14, 2007
Compliance Home,Consistent with these recommendations, FOSAMAX PLUS D (70 mg alendronate/5600 IU vitamin D3) is now the appropriate dose for most postmenopausal patients

Piribo: New Report on the Women's Health Pharmaceutical Market to 2011  -  May 11, 2007
PR Web (press release),Fosamax, with an indication in osteoporosis Fosamax and its reformulated counter part Fosamax PLUS D which accrued combined sales of $2845m in 2005.

Focus on the Women's Health Market to 2011  -  26 Apr 2007
PharmaLive.com (press release),Fosamax, with an indication in osteoporosis Fosamax and its reformulated counter part Fosamax PLUS D which accrued combined sales of $2845m in 2005.

Merck Reports Strong Financial Results for First-Quarter 2007  -  Apr 19, 2007
PharmaLive.com (press release),Global sales for FOSAMAX and FOSAMAX PLUS D (marketed as FOSAVANCE throughout the European Union) were $742 million for the first quarter, representing a

Merck's Q1 profit rises  -  Apr 20, 2007
Pharma Times (subscription),Revenues from Fosamax (alendronate) and Fosamax Plus D were less solid, faling by 2% from the previous year to $742 million.

Strong Sales Of Allergic Drug Lifts Merck Q1 Profit By 12%, Sets ...  -  Apr 19, 2007
Trading Markets,...comparable 2006-first quarter, whereas its Fosamax and Fosamax Plus D's global sales fell 2% to $742 million from the corresponding period last year.

Study Finds TV Pharma Ads Less Effective Than Print  -  Apr 11, 2007
MediaPost Publications,For example, 43% of people who suffer with osteoporosis recalled a TV ad for Fosamax Plus D compared with only 19% of non-sufferers.

roy pIrRUNg column: Vitamin D important to health  -  Mar 2, 2007
Sheboygan Press,Last August, the FDA approved a new drug called Fosamax Plus D. This drug is an improvement over Merck & Co.'s most prescribed osteoporosis medication,

People's Pharmacy: Toprol could ease migraines  -  Feb 10, 2007
Bryan College Station Eagle,Q: I have seen full-page ads for Fosamax Plus D in my local newspaper. Why is Merck spending so much money advertising this osteoporosis drug?

Merck Announces 2006 Financial Results that Demonstrate Solid ...  -  Jan 30, 2007
Business Wire (press release),Global sales for FOSAMAX and FOSAMAX PLUS D (marketed as FOSAVANCE throughout the European Union) were $789 million for the fourth quarter, comparable to

Merck Q4 Profit Declines 58% On Charges, Dip In Zocor Sales; EPS ...  -  Jan 30, 2007
Trading Markets,Global sales for osteoporosis drug Fosamax and Fosamax Plus D were $789 million for the fourth quarter. Vytorin sales grew 56% and generated sales of $553

Are heartburn, osteoporosis linked?  -  Jan 17, 2007
Daily Press,Q: I have seen full-page ads for Fosamax Plus D in my local newspaper. Why is Merck spending so much money advertising this osteoporosis drug?

Jaw Infections/Osteoporosis Drugs  Nov 3, 2006
Merck, the manufacturer of FOSAMAX®, FOSAMAX Plus D™, and Boniva®, has acknowledged receiving reports of jaw osteonecrosis associated with these drugs. ... -WSOCtv.com, Merck Announces Strong Financial Results for the Third Quarter ...  Oct 20, 2006
Global sales for FOSAMAX and FOSAMAX PLUS D (marketed as FOSAVANCE throughout the European Union (EU)) were $771 million for the third quarter, representing a ... -PharmaLive.com (press release), Higher Persistency Rates Seen with FOSAMAX(R) Once Weekly ...  Sep 19, 2006
The standard dosing regimen for FOSAMAX and FOSAMAX PLUS D(TM) includes swallowing the tablet with six to eight ounces of plain water the first thing upon ... -Business Wire

Banyu Receives Japan Manufacturing Approval For Fosamax, Treatment ...  Aug 5, 2006
Banyu Pharmaceutical Co., Ltd. obtained manufacturing approval for Fosamax Plus D - generic name: aledronate sodium - on July 26. ... -Medical News Today

Banyu Receives Japan Manufacturing Approval for Fosamax, Treatment ...  Aug 3, 2006
Tokyo, Aug 3, 2006 (JCN) - Banyu Pharmaceutical Co., Ltd. obtained manufacturing approval for Fosamax Plus D - generic name: aledronate sodium - on July 26. ... -Japan Corporate News

Bone drug treatment can damage jaw  Jun 26, 2006
Fosamax and Fosamax Plus D are the most widely prescribed medicines worldwide for postmenopausal, male and glucocortaid-induced osteoporosis, according to Merck ... -Monterey County Herald



Merck Announces Strong Financial Results for the First Quarter ...  Apr 20, 2006
FOSAMAX and FOSAMAX PLUS D (launching under the name FOSAVANCEthroughout the European Union) together remain the most-prescribedmedicine worldwide for the ... - Finanzen.net

Merck Well-Positioned to Regain Industry-Leadership Position, CEO ...  Apr 25, 2006
Merck received FDA approval for two new products: FOSAMAX Plus D and PROQUAD; while new indications were approved for EMEND and SINGULAIR. ... - Finanzen.net





Merck Sued Over Fosamax Health Risks  11 Apr 2006
...request, he said. Fosamax and Fosamax Plus D together are the most-prescribed medicine for osteoporosis in post-menopausal women. - Los Angeles Times

Merck Earnings Top Estimates  Jan 31, 2006
12% to $819 million; sales of blood-pressure drugs Cozaar and Hyzaar rose 2% to $782 million; sales osteoporosis medication Fosamax and Fosamax Plus D fell 5 ... - TheStreet.com

Merck Announces Strong Full-Year and Fourth-Quarter 2005 Earnings ...  Jan 31, 2006
FOSAMAX and FOSAMAX PLUS D (launching under the name FOSAVANCE throughout the European Union) together remain the most-prescribed medicine worldwide for the ... - TMCnet

Merck profits edge ahead in fourth quarter  Feb 1, 2006
...although the osteoporosis drug Fosamax (alendronate) declined 5% to $789 million, with the launch of a new formulation (Fosamax Plus D/Fosavance) failing to ... - Pharma Times (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional